FCPM III SERVICES B.V.

CIK: 0002013410Latest portfolio: $762.9M · Q4 2025

Holdings

10

Total Value

$762.9M

New Positions

2

Closed Positions

1

Top Holdings

#StockSharesValue% PortfolioChangeType
1
NAMSNEWAMSTERDAM PHARMA COMPANY
9,198,900$322.7M42.30%-13,484
2
DYNDYNE THERAPEUTICS INC
5,462,846$106.9M14.01%
3
ENGNENGENE HOLDINGS INC
9,632,561$87.0M11.40%
4
RAPTRAPT THERAPEUTICS INC
1,833,333$62.1M8.14%+1.5M
5
MPLTMAPLIGHT THERAPEUTICS INC
3,226,400$56.7M7.43%NEW
6
VORVOR BIOPHARMA INC
3,617,354$47.3M6.20%+3.2M
7
REPLREPLIMUNE GROUP INC
2,808,368$27.3M3.58%-1,350,000
8
BCYCBICYCLE THERAPEUTICS PLC
3,468,430$24.6M3.22%+16K
9
CBIOCRESCENT BIOPHARMA INC.
1,677,852$19.9M2.61%NEW
10
ENGNWENGENE HOLDINGS INC
2,878,148$8.5M1.12%

Quarterly Changes

New Positions

Closed Positions

Increased Positions

NameSharesChange
BCYC3.5M+16K

Decreased Positions

NameSharesChange
REPL2.8M-1350000
NAMS9.2M-13484
RAPT1.8M1.5M
VOR3.6M3.2M

Sector Breakdown

Healthcare100.0% ($3.2269610685286984e+41T)

Filing History

QuarterFiling DatePortfolio ValueHoldings
Q4 2025Feb 17, 2026$762.9M14
Q3 2025Nov 14, 2025$500.4B13
Q2 2025Aug 14, 2025$369.2B12
Q1 2025May 15, 2025$413.7B12
Q4 2024Feb 14, 2025$592.4B12

Fund Information

CIK0002013410
Most Recent FilingFeb 17, 2026
Number of Filings5

FCPM III SERVICES B.V. is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $762.9M across 10 holdings. The largest position is NEWAMSTERDAM PHARMA COMPANY (NAMS), representing 42.3% of the portfolio. Compared to the previous quarter, the fund opened 2 new positions and closed 1 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.